According to polling, in April 2020, at the outbreak of the pandemic, 71.5% of respondents reported having "a lot of trust" in physicians and hospitals. By January 2024, that number had plummeted to 40.1%.

Unfortunately, trust in our healthcare system and its institutions has been undermined by a belief that decisions are being made not based on what is in the best interest of Americans' healthcare but on what is in the best interest of corporate bottom lines.

To restore faith in our system, we need research and treatment that is focused on the patient's health, not just profit. That's where The Wellness Company comes in.

Dr. Peter McCullough and a number of his colleagues at The Wellness Company have recently authored a first-of-its-kind study of the application of Ivermectin + Mebendazole in the treatment of cancer.

84% of Cancer Patients Reported a Clinical Benefit

In this human observational analysis, off-label use of Ivermectin + Mebendazole showed a remarkable 84% Clinical Benefit Ratio in the treatment of cancer. These results indicate that the inexpensive and safe off-label applications of these medications could be an important breakthrough in the treatment of cancer.

The report analyzed 197 cancer patients who were prescribed ivermectin and mebendazole off label. Participants received compounded oral capsules containing 25 mg of ivermectin and 250 mg of mebendazole. After 6 months, participants reported an 84% Clinical Benefit Ratio. With 48% of participants reporting regression or no evidence of cancer, while 36% reported disease stability. Only 15.6% of participants reported disease progression.

Cancer remains one of the leading causes of death globally, with conventional treatments such as chemotherapy, radiation therapy, and targeted agents frequently limited by significant toxicity, high cost, development of resistance, and variable long-term efficacy.

The experts at The Wellness Company undertook this study because ivermectin and mebendazole have demonstrated highly promising anticancer activity in preclinical models. But despite compelling preclinical data and documented safe use in cancer patients, robust clinical evidence evaluating the ivermectin–mebendazole combination in oncology remains limited.

According to Dr. McCullough:

This study reveals an exciting new potential that should expand the consideration of ivermectin and mebendazole for inclusion in the treatment of multiple cancer types. We urgently need a full-fledged scientific investigation into this class of medications and their impact on cancer treatment.